Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Borer

Showing results (291-300 of 394) with videos related to

Pageof 40
Sort By:
European Journal of Heart Failure|March 6, 2013
Risk following hospitalization in stable chronic systolic heart failurePutte Abrahamsson, Karl Swedberg, Jeffrey S Borer, et al.
European Heart Journal|August 29, 2012
Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT StudyJeffrey S Borer, Michael Böhm, Ian Ford, et al.
Cardiology|July 15, 2000
Preoperative predictors of late postoperative outcome among patients with nonischemic mitral regurgitation with 'high risk' descriptors and comparison with unoperated patientsD Wencker, J S Borer, C Hochreiter, et al.
ESC Heart Failure|July 10, 2023
Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial)Amr Abdin, Michel Komajda, Jeffrey S Borer, et al.
The American Journal of Cardiology|March 17, 2015
Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failureAbhishek Sharma, Carl J Lavie, Jeffrey S Borer, et al.
American Heart Journal|May 1, 1987
Relationship of the electrocardiographic response to exercise to geometric and functional findings in aortic regurgitationP Kligfield, O Ameisen, P M Okin, et al.
The New England Journal of Medicine|March 13, 2018
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with GoutWilliam B White, Kenneth G Saag, Michael A Becker, et al.
Cardiology|November 18, 2014
Role of oral factor Xa inhibitors after acute coronary syndromeAbhishek Sharma, Akash Garg, Jeffrey S Borer, et al.
Circulation. Heart Failure|March 23, 2012
When to stop a clinical trial early for benefit: lessons learned and future approachesFaiez Zannad, Wendy Gattis Stough, John J V McMurray, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 10, 2022
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes TrialKenneth G Saag, Michael A Becker, William B White, et al.
Pageof 40

Showing results (291-300 of 394) with videos related to

Sort By:
Pageof 40
European Journal of Heart Failure|March 6, 2013
Risk following hospitalization in stable chronic systolic heart failurePutte Abrahamsson, Karl Swedberg, Jeffrey S Borer, et al.
European Heart Journal|August 29, 2012
Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT StudyJeffrey S Borer, Michael Böhm, Ian Ford, et al.
Cardiology|July 15, 2000
Preoperative predictors of late postoperative outcome among patients with nonischemic mitral regurgitation with 'high risk' descriptors and comparison with unoperated patientsD Wencker, J S Borer, C Hochreiter, et al.
ESC Heart Failure|July 10, 2023
Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial)Amr Abdin, Michel Komajda, Jeffrey S Borer, et al.
The American Journal of Cardiology|March 17, 2015
Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failureAbhishek Sharma, Carl J Lavie, Jeffrey S Borer, et al.
American Heart Journal|May 1, 1987
Relationship of the electrocardiographic response to exercise to geometric and functional findings in aortic regurgitationP Kligfield, O Ameisen, P M Okin, et al.
The New England Journal of Medicine|March 13, 2018
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with GoutWilliam B White, Kenneth G Saag, Michael A Becker, et al.
Cardiology|November 18, 2014
Role of oral factor Xa inhibitors after acute coronary syndromeAbhishek Sharma, Akash Garg, Jeffrey S Borer, et al.
Circulation. Heart Failure|March 23, 2012
When to stop a clinical trial early for benefit: lessons learned and future approachesFaiez Zannad, Wendy Gattis Stough, John J V McMurray, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 10, 2022
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes TrialKenneth G Saag, Michael A Becker, William B White, et al.
Pageof 40